CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Open-market sale SVP, Chief Technical Officer sold 7,549 shares at $1.73 ($13,060)
- 4 Open-market sale President and CEO sold 95,269 shares at $1.80 ($171,484)
- 4 Open-market sale CHIEF FINANCIAL OFFICER sold 24,001 shares at $1.76 ($42,242)
- 4 Open-market sale SVP, General Counsel sold 22,900 shares at $1.76 ($40,304)
- 4 Open-market sale SVP, Finance sold 4,167 shares at $1.72 ($7,167)
- 4 Open-market sale EVP of R&D sold 35,700 shares at $1.77 ($63,189)
- 4 Derivatives Options or other derivatives
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Open-market sale EVP of R&D sold 26,269 shares at $1.56 ($40,980)
- 144 Insider Sale of Securities
- 4 Option exercise Director acquired 47,700 shares (option exercise)
- 4 Open-market sale SVP, Chief Technical Officer sold 786 shares at $1.22 ($959)
- 144 Insider Sale of Securities
Page 4 of 30 · 587 filings